Henichart JP[au] - Search Results

Year	Number of Results
1977	1
1979	1
1980	3
1981	4
1982	2
1983	1
1984	3
1985	5
1986	2
1987	6
1988	5
1989	6
1990	8
1991	6
1992	17
1993	6
1994	11
1995	5
1996	3
1997	2
1998	1
1999	3
2000	4
2001	7
2002	7
2003	8
2004	8
2005	9
2006	10
2007	9
2008	5
2009	2
2010	2
2011	3
2012	1
2014	1
2022	0

1

COX-2/5-LOX dual acting anti-inflammatory drugs in cancer chemotherapy.

Goossens L, Pommery N, Hénichart JP. Goossens L, et al. Among authors: henichart jp. Curr Top Med Chem. 2007;7(3):283-96. doi: 10.2174/156802607779941369. Curr Top Med Chem. 2007. PMID: 17305571 Review.

2

DNA recognition by intercalator-minor-groove binder hybrid molecules.

Bailly C, Hénichart JP. Bailly C, et al. Among authors: henichart jp. Bioconjug Chem. 1991 Nov-Dec;2(6):379-93. doi: 10.1021/bc00012a001. Bioconjug Chem. 1991. PMID: 1666838 Review. No abstract available.

3

Involvement of PI3K/Akt pathway in prostate cancer--potential strategies for developing targeted therapies.

Pommery N, Hénichart JP. Pommery N, et al. Among authors: henichart jp. Mini Rev Med Chem. 2005 Dec;5(12):1125-32. doi: 10.2174/138955705774933356. Mini Rev Med Chem. 2005. PMID: 16375758 Review.

4

Drug-DNA sequence-dependent interactions analysed by electric linear dichroism.

Bailly C, Hénichart JP, Colson P, Houssier C. Bailly C, et al. Among authors: henichart jp. J Mol Recognit. 1992 Dec;5(4):155-71. doi: 10.1002/jmr.300050406. J Mol Recognit. 1992. PMID: 1339484 Review.

5

[Involvement of PI3K/Akt pathway in prostate cancer. Potential strategies for developing targeted therapies].

Pommery N, Hénichart JP. Pommery N, et al. Among authors: henichart jp. Ann Pharm Fr. 2005 Jan;63(1):69-75. doi: 10.1016/s0003-4509(05)82253-9. Ann Pharm Fr. 2005. PMID: 15803103 Review. French.

6

(2RS,5SR,6SR)-methyl 4-{cis-2-[3-fluoro-5-(4-methoxy-3,4,5,6-tetrahydro-2H-pyran-4-yl)phenoxymethyl]-6-hydroxy-3-phenylmorpholino}benzenesulfinate.

Charlier C, Delayen A, Norberg B, Hénichart JP, Wouters J. Charlier C, et al. Among authors: henichart jp. Acta Crystallogr C. 2006 Feb;62(Pt 2):o92-4. doi: 10.1107/S0108270106001065. Epub 2006 Jan 21. Acta Crystallogr C. 2006. PMID: 16456296

7

Mechanisms leading to COX-2 expression and COX-2 induced tumorigenesis: topical therapeutic strategies targeting COX-2 expression and activity.

Telliez A, Furman C, Pommery N, Hénichart JP. Telliez A, et al. Among authors: henichart jp. Anticancer Agents Med Chem. 2006 May;6(3):187-208. doi: 10.2174/187152006776930891. Anticancer Agents Med Chem. 2006. PMID: 16712448 Review.

8

New bis-catechols 5-lipoxygenase inhibitors.

Dupont R, Goossens JF, Cotelle N, Vrielynck L, Vezin H, Hénichart JP, Cotelle P. Dupont R, et al. Among authors: henichart jp. Bioorg Med Chem. 2001 Feb;9(2):229-35. doi: 10.1016/s0968-0896(00)00258-3. Bioorg Med Chem. 2001. PMID: 11249115

9

Synthesis and biological activity of N-aroyl-tetrahydro-gamma-carbolines.

Bridoux A, Millet R, Pommery J, Pommery N, Henichart JP. Bridoux A, et al. Among authors: henichart jp. Bioorg Med Chem. 2010 Jun 1;18(11):3910-24. doi: 10.1016/j.bmc.2010.04.034. Epub 2010 Apr 18. Bioorg Med Chem. 2010. PMID: 20451397

10

[Metabolic treatment of cancer].

Vamecq J, Mestdagh N, Henichart JP, Poupaert J. Vamecq J, et al. Among authors: henichart jp. J Pharm Belg. 1990 Nov-Dec;45(6):361-74. J Pharm Belg. 1990. PMID: 2086759 Review. French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results